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Richard B. Weller, MD, FRCP (Ed)a,b Edinburgh, Glasgow, and Dundee, United Kingdom
Background: Mutations in the gene encoding filaggrin (FLG),
an epidermal structural protein, are the strongest risk factor
identified for the development of atopic dermatitis (AD). Up to
50% of patients with moderate-to-severe AD in European
populations have FLG-null alleles compared with a general
population frequency of 7% to 10%.
Objective: This study aimed to investigate the relationship
between FLG-null mutations and epidermal antigen-presenting
cell (APC) maturation in subjects with and without AD.
Additionally, we investigated whether the cis isomer of urocanic
acid (UCA), a filaggrin breakdown product, exerts
immunomodulatory effects on dendritic cells.
Methods: Epidermal APCs from nonlesional skin were assessed
by using flow cytometry (n 5 27) and confocal microscopy
(n 5 16). Monocyte-derived dendritic cells from healthy
volunteers were used to assess the effects of cis- and trans-UCA
on dendritic cell phenotype by using flow cytometry (n 5 11).
Results: Epidermal APCs from FLG-null subjects had increased
CD11c expression. Confocal microscopy confirmed this and
additionally revealed an increased number of epidermal CD831
Langerhans cells in FLG-null subjects. In vitro differentiation in
the presence of cis-UCA significantly reduced costimulatory
molecule expression on monocyte-derived dendritic cells from
healthy volunteers and increased their ability to induce a
regulatory T-cell phenotype in mixed lymphocyte reactions.
Conclusions: We show that subjects with FLG-null mutations
have more mature Langerhans cells in nonlesional skin
irrespective of whether they have AD. We also demonstrate that
cis-UCA reduces maturation of dendritic cells and increases
their capacity to induce regulatory T cells, suggesting a
novel link between filaggrin deficiency and immune
dysregulation. (J Allergy Clin Immunol 2016;138:482-90.)
Key words: Filaggrin, atopic dermatitis, Langerhans cells, urocanic
acid, costimulatory molecules
Mutations in the gene encoding filaggrin (FLG), an epidermal
structural protein, are associated with different phenotypes:
atopic dermatitis (AD), ichthyosis vulgaris (IV), or clinically
normal skin. Up to 50% of patients with moderate-to-severe
AD in European populations have at least 1 FLG-null allele1
compared with a general population frequency of 7% to 10%.2
Although the finding of such a robust gene association has
enlivened research into what had been considered a complex
polygenic disorder, the relationship between FLG-null mutations
and AD has not yet been clearly elucidated.
The ‘‘outside-inside’’ theory of the pathogenesis of AD pro-
poses that a deficient skin barrier is the primary abnormality
driving the disease, allowing allergens, antigens, and microbial
danger signals to penetrate the epidermis and activate local
antigen-presenting cells (APCs). Human epidermis is colonized
by a specialized subset of APCs known as Langerhans cells (LCs).
In patients with AD, persistent LC stimulation through a defective
skin barrier can result in chronic TH2-driven atopic inflamma-
tion.3 Because filaggrin is involved in collapsing keratinocytes
to form the densely packed stratum corneum, it is thought to
play a crucial role in maintaining physical skin barrier integrity.4,5
Therefore the outside-inside theory suggests a causative link be-
tween genetic filaggrin deficiency and the development of AD.
Filaggrin breakdown products might also be important in skin
barrier function. Filaggrin is rich in histidine, which is converted in
the epidermis to trans-urocanic acid (trans-UCA). This in turn is
naturally converted to cis-UCA in the skin on exposure to UV radi-
ation.6 cis-UCA has been previously investigated as a potential
immunomodulator of allergic responses in the skin, and it has
been shown that topical7 or systemic8 administration of cis-UCA
suppresses skin immune responses to viral infection inmice. Given
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Abbreviations used
AD: Atopic dermatitis
APC: Antigen-presenting cell
FACS: Fluorescence-activated cell sorting
FITC: Fluorescein isothiocyanate
FLG: Filaggrin gene
FoxP3: Forkhead box protein 3
IV: Ichthyosis vulgaris
LC: Langerhans cell
LTA: Lipotechoic acid
MDCC: Monocyte-derived dendritic cell
MFI: Mean fluorescence intensity
PD-L1: Programmed death ligand 1
PE: Phycoerythrin
PerCP: Peridinin-chlorophyll-protein complex
SASSAD: Six Area, Six Sign Atopic Dermatitis Score
TEWL: Transepidermal water loss
UCA: Urocanic acid
WT: Wild-type
systemically to mice, it induces tolerance to cutaneous allergens,9
whereas in human subjects topical application of cis-UCA blunts
the cell-mediated response to dinitrochlorobenzene.10 Although
topical cis-UCA is currently in early-phase trials as a possible
treatment for AD,11 its exact mode of action is not known.
In this study we investigated the maturation state of epidermal
APCs in subjects with FLG-null mutations, looking for any
differences in APC phenotype between FLG-null subjects with
and without AD and any correlation with skin barrier function.
We also investigated whether cis-UCA affects dendritic cell
phenotype and function in vitro.
METHODS
Recruitment and characterization of volunteers
The study was approved by the Lothian Research Ethics Committee
(07/MRE00/109), and informed written consent was obtained from all
participants. Subjects were recruited from general outpatient and patch test
clinics at the Department of Dermatology, Royal Infirmary of Edinburgh
(patients with AD only), and medical students and staff at the University of
Edinburgh and the Southern General Hospital Glasgow. Diagnosis of AD was
based on the UK Working Party’s Diagnostic Criteria.12 Subjects were
interviewed about personal and family history of atopy and current and past
management of AD and were assessed for symptoms and signs of AD and IV
by means of both questionnaire and examination.13 AD severity was measured
by using the Six Area, Six Sign Atopic Dermatitis severity score.14 No subjects
had usedoral or topical steroids for at least 1week before the study.Whole blood
was obtained from heathy volunteers at the MRC Centre for Inflammation
Research, University of Edinburgh (ethics approval 08/S1103/38).
Genotyping
Genotyping of subjects involved in physical skin barrier assessment and
suction blister analysis by flow cytometry was performed with a TaqMan-
based allelic discrimination assay (Applied Biosystems, Foster City, Calif) for
the 2 most common FLG mutations in European populations (2282del4 and
R501X). Samples were analyzed at Source Bioscience (Nottingham, United
Kingdom) or by the Human Genetics Unit, University of Dundee. Subjects
involved in suction blister analysis using confocalmicroscopywere genotyped
for the 4 most common FLG mutations in European populations (2282del4,
R501X, S3247X, and R2447X) at the Wellcome Trust Clinical Research Fa-
cility, Western General Hospital, Edinburgh, Scotland. Probes and primers
were as described previously.15
Suction blisters
Suction blister cups were applied to the upper inner arm to produce
epidermal blisters with a suction blister device (InnoKas Medical Oy,
Kempele, Finland). Each cup formed up to 5 blisters 5 mm in diameter after
90 to 120 minutes at a suction pressure of 400 mbar applied at 10-second
intervals. Suction blisters from patients with AD were taken from clinically
uninvolved skin. For details of the quantification of cis- and trans-UCA
isomers in suction blister fluid, see the Methods section in this article’s Online
Repository at www.jacionline.org.
Measurement of transepidermal water loss
Subjects were asked not to take antihistamines or apply any topical
treatments, including emollients, for 3 days before the study. All physiologic
measurements were taken from uninvolved flexor forearm skin (4 cm below
the antecubital fossa) after 10 minutes of acclimatization to standardized
conditions (208C-228C; humidity, 40% to 60%). Measurements were
performed in an open-top box to limit air convection currents and
condensation.16 Transepidermal water loss (TEWL) was measured with the
Tewameter TM300 (Courage and Khazaka, Cologne, Germany) with an
open-chamber probe. Measurements were repeated 3 times.
Tape stripping
Tape stripping was performed with 14-mmD-Squame tape discs (CuDerm,
Dallas, Tex). A cylindrical weight applying a pressure of 225 g/cm2 was
used for 10 seconds before the tapes were removed unidirectionally with
forceps.17 The number of tape strips required to abrogate the permeability
barrier (TEWL >20 g/m2/h)18 was recorded by measuring TEWL after each
tape strip.
Phenotypic analysis of epidermal APCs
For flow cytometry, blister roofs were incubated at 378C for 30 minutes
with 0.05% trypsin in PBS before manual disaggregation. PBS containing 1%
FCS was added, and the cells were washed by means of centrifugation
(10 minutes at 300g). The pellet was resuspended in 1 mL of fluorescence-
activated cell sorting (FACS) wash buffer (BD Biosciences, Oxford, United
Kingdom) containing 5% mouse serum and incubated for 10 minutes on
ice, washed, and resuspended in 200 mL of FACS wash containing 5% mouse
serum. For details of antibody staining, please see the Methods section in this
article’s Online Repository. Samples were collected with a BD LSR Fortessa
Flow cytometer (BD Biosciences). Anti-mouse CompBead Plus (BD
Biosciences) was used to calibrate color compensation. Results were analyzed
with FlowJo software (TreeStar, Ashland, Ore).
For confocal microscopy, epidermal samples were fixed for 30 minutes in
90% acetone/10% methanol and then washed in 3 changes of PBS (Gibco,
Grand Island, NY) for 10 minutes each. Samples were incubated with
antibodies for 1 hour in PBS with 0.1% BSA (Sigma-Aldrich, St Louis, Mo)
and then washed 3 times in PBS. For details of antibody staining panels, see
the Methods section in this article’s Online Repository. Staining was done at
room temperature, and samples were protected from light. Samples were
mounted on Superfrost Plus slides (BDH Laboratory Supplies, Dorset, United
Kingdom) in Permafluor (Thermo Scientific, Waltham, Mass) and stored at
28C to 58C.
Slides were observed with a Leica SP5 confocal microscope (Leica
Microsystems,Wetzlar, Germany) with a340 oil immersion objective. Image
stacks were acquired in 1.01-mm slices through the epidermis. Images were
deconvolved with Huygens Essential Software (Scientific Volume Imaging,
Hilversum, The Netherlands). Basic image analysis was performed with
ImageJ software (National Institutes of Health, Bethesda, Md), and
3-dimensional image analysis was performed with Volocity 5.5 (PerkinElmer,
Waltham, Mass). LC volumes were calculated by using CD1a staining as a
proxy measure. Individual cells were identified by using an intensity
threshold, and 50 cell volumes were averaged to produce a mean LC volume
for each subject. The cell volume enclosed by CD11c cell-surface expression
was also calculated as above.
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Generation of monocyte-derived dendritic cells
PBMCs were obtained from whole blood by means of Ficoll gradient
centrifugation (Ficoll-Paque PLUS;GEHealthcare, Buckinghamshire, United
Kingdom). CD141monocytes were isolated bymeans of positive selection by
using magnetic-activated cell sorting with CD141 microbeads, according to
the manufacturer’s instructions (Miltenyi Biotec, Bergisch Gladbach,
Germany). CD141monocytes were cultured in 12-well plates (Nunclon Delta
surface, Thermo Scientific) at a density of 23 106 cells/mL in RPMI 1640 cul-
ture medium (Gibco) buffered with 20mmol/LHEPES, 5% humanAB serum,
and 1% L-glutamine for 7 days. Medium was supplemented with 50 ng/mL
GM-CSF (PeproTech, Rocky Hill, NJ) and 15 ng/mL IL-4 (Invitrogen,
Carlsbad, Calif), and cis- or trans-UCA (Sigma-Aldrich) was added to wells
at concentrations of 10 or 100 mg/mL on day 0. These concentrations were
chosen for the in vitro experiments to best mimic physiologic concentra-
tions.19 Fresh medium supplemented with cytokines and UCAwas added on
days 3 and 5. A portion of the immature dendritic cells was collected on
day 7 for analysis; remaining cells were stimulated with LPS (1 ng/mL) or
lipotechoic acid (LTA) (10 mg/mL) and harvested on day 8 when monocyte-
derived dendritic cell (MDCC) viability was at least 90% in cultures with
and without cis- and trans-UCA. All cultures were protected from light.
Flow cytometric analysis of MDDCs
For details of antibody staining panels, see the Methods section in this
article’s Online Repository.
MDCC and CD4 T-cell coculture
Immature MDCCs conditioned with or without 100 mg/mL cis-UCAwere
cocultured with allogeneic CD4 T cells stained with proliferation dye EF670
(eBioscience, San Diego, Calif) at a ratio of 1:10 in 96-well plates. CD4 T-cell
isolation details are presented in the Methods section in this article’s Online
Repository. Cells were cocultured at 378C in a 5%CO2 humidified atmosphere
for 5 days. Anti-CD3/CD28 (1mg/mL, eBioscience) was added to a portion of
CD4 T cells as a positive control. The proliferation of CD4 T cells and the
proportion of CD41CD251 forkhead box protein 3 (FoxP3)1 CD1272 cells
were analyzed by using flow cytometry. For details of antibody staining, see
the Methods section in this article’s Online Repository.
Statistical analysis
Statistical analysis was performed with Prism 6 software (GraphPad
Software, San Diego, Calif). Mann-WhitneyU, Kruskal-Wallis, and Friedman
tests with Dunn posttest comparisons were used to analyze data. Data are
presented as means 6 SDs, unless otherwise stated. P values of less than
.05 were considered significant.
RESULTS
Subjects
Two hundred sixty-four subjects were genotyped. Of these, 117
were clinically phenotyped and participated in further studies.
Seventy-seven had AD (all with mild-to-moderate disease), of
whom 56 were wild-type (WT) and 21 had FLG-null mutations
(18 FLG heterozygote [FLG1/-] and 3 FLG homozygote
[FLG2/2]). The remaining 40 subjects had clinically
normal skin; 27 were WT, and 13 had FLG-null mutations (all
FLG1/2). No subjects met the diagnostic criteria for IV.
Mean Six Area, Six Sign Atopic Dermatitis scores were very
similar between AD groups involved in each part of the study
(Table I). Total serum IgE levels (in international units per
milliliter) were measured in 78 of the 84 subjects who had
TEWL measured and tape-stripping performed. As expected,
IgE levels were significantly higher in subjects with AD
(629.5 6 1286 IU/mL) compared with those in subjects without
AD (54 6 59.3 IU/mL, P < .0001). However, FLG status
did not influence IgE levels in AD subjects as there was no
significant difference in IgE levels between WT subjects with
AD (678 6 1374 IU/mL) and FLG-null subjects with AD
(443 6 892 IU/mL, P 5 .62).
LCs have higher CD11c expression in FLG-null
subjects with and without AD
Twenty-seven subjects had suction blister samples analyzed by
flow cytometry (for gating strategy, see Fig E1 in this article’s
Online Repository at www.jacionline.org). Total live cell yields
ranged from 5,000 to 65,000, without significant differences
between groups. Therewas no difference in the time taken to raise
blisters within the different subject groups. Proportions of
HLA-DR1CD1a1 cells were similar between the groups
TABLE I. Clinical assessment of genotyped subjects
WT non-AD WT AD FLG non-AD FLG AD
TEWL and tape-stripping group
No. 18 46 8 12
Age (y [range]) 28 (19-59) 35 (18-76) 28 (19-58) 35 (22-57)
Male/female sex 8/10 16/30 4/4 5/7
SASSAD 6 SD NA 11 6 9.3 NA 12 6 7.5
IgE 6 SD (IU/mL)* 63 6 63 (n 5 14) 678 6 1374 (n 5 46) 33 6 47 (n 5 6) 443 6 892 (n 5 12)
Asthma 2 (11%) 15 (33%) 2 (25%) 5 (42%)
Hay fever 1 (6%) 27 (59%) 1 (13%) 4 (33%)
Suction blister flow cytometry group
No. 8 7 4 8
Age (y [range]) 31 (20-55) 42 (27-76) 21 (19-25) 37 (27-57)
Male/female sex 3/5 3/4 3/1 3/5
SASSAD 6 SD NA 6 6 4 NA 8 6 3
Suction blister immunostaining group
No. 4 3 5 4
Age (y [range]) 34 (21-51) 21 (20-21) 35 (20-54) 40 (22-56)
Male/female sex 3/1 2/1 4/1 2/2
SASSAD 6 SD NA 12 6 8 NA 15 6 8
NA, Not applicable; SASSAD, Six-Area, Six-Sign Atopic Dermatitis score.
*P 5 .0001, AD versus non-AD.
P 5 .0001, AD versus non-AD.
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(2.9% to 4.3%). There was a significantly higher proportion of
CD11chi cells among HLA-DR1CD1a1 cells in FLG-null than
in WT subjects, with the highest level in FLG-null subjects
without AD (all FLG-null subjects: 56% 6 10.2% CD11chi cells
vs all WT subjects: 34% 6 15.6%, P 5 .0006, Fig 1).
Sixteen subjects had suction blister samples analyzed by using
confocal microscopy. There was no significant difference in
epidermal thickness between the different groups, as calculated
by the mean number of z-stack slices required to visualize
each sample (see Fig E2 in this article’s Online Repository at
www.jacionline.org). All CD1a1 dendritic cells in the blister
roofs were langerin positive, confirming that they were all LCs
(Fig 2, A). The mean number of LCs per square millimeter, the
mean volume of LCs, and the mean number of dendrites per LC
were similar between the groups (data not shown). Comparing
all FLG-null subjects with all WT subjects, the mean volume
enclosed by CD11c staining (in cubic micrometers) was
significantly higher in FLG-null subjects (all FLG-null subjects:
941.2 6 690.9 mm3 vs all WT subjects: 257.5 6 324.3 mm3,
P 5 .04; Fig 2, B).
More CD831 LCs in FLG-null subjects with and
without AD
Analysis of confocal microscopy images revealed occasional
CD831 LCs, which also showed increased expression of
HLA-DR (see Fig E3 in this article’s Online Repository at
www.jacionline.org). Compared with all WT subjects, the num-
ber of CD831 LCs was significantly higher in FLG-null subjects
(all FLG-null subjects: 2.236 1.2 CD831 LCs per 100 LCs vs all
WT subjects: 0.756 0.4 CD831 LCs per 100 LCs, P5 .01; Fig 2,
C). There were no significant differences in the mean volume
enclosed by HLA-DR staining between groups (data not shown).
FLG status only affects barrier function in patients
with AD
Resting TEWLwasmeasured in 84 subjects, and the number of
tape strips required to reach a TEWL of greater than 20 g/m2/h
was measured in 82 subjects. TEWL was significantly higher in
the FLG-null AD group than in the WT AD group (FLG-null
AD: 8.7 6 1.9 g/m2/h vs WT AD: 8.1 6 5.6 g/m2/h, P 5 .02;
Fig 3, A). Two WT subjects with AD with very high resting
TEWL of greater than 2 SDs from the mean were identified as
statistical outliers by using a Robust regression and Outlier
remover (ROUT) test (Q 5 0.2%). When these subjects were
excluded from the analysis, the mean TEWL in theWTAD group
was 7.16 2.3 g/m2/h (P5.007,FLG-null AD vsWTAD groups).
The number of tape strips required to reach a TEWL of greater
than 20 g/m2/h per hour was significantly lower in the FLG-null
AD group compared with all other groups (FLG-null AD:
11.25 6 2 strips vs WTAD: 14.7 6 4.9 strips vs FLG-null non-
AD: 17.00 6 3.9 strips vs WT non-AD: 18.9 6 5.9 strips,
P 5 .0001; Fig 3, B). Interestingly, subjects without AD with
and without FLG-null mutations required a similar number of
tape strips to reduce the permeability barrier.
Cis-UCA reduces costimulatory molecule
expression in MDCCs
Although immature MDCCs at day 7 had only a low level of
expression of HLA-DR and costimulatory molecules (see
Table E1 and Fig E4 in this article’s Online Repository at
www.jacionline.org), cells conditioned with 100mg/mL cis-UCA
showed reduced expression of CD86, programmed death ligand 1
(PD-L1), HLA-DR, and CD40 compared with that seen in control
cells (CD86 mean fluorescence intensity [MFI]: 38136 1414 vs
6275 6 2086, P < .0001; PD-L1 MFI: 96 6 44 vs 149 6 88,
P < .0001; HLA-DR MFI: 863 6 549 vs 1112 6 627, P 5 .001;
CD40 MFI: 5076 378 vs 7086 477, P5 .0001; Fig 4), whereas
conditioning with trans-UCA had no effect on expression of these
molecules. Expression of CD1a and CD11c did not change with
cis-UCA conditioning (data not shown).
MDCC stimulation with LPS or LTA on day 7 increased
HLA-DR and costimulatory molecule expression on day 8, as
expected (see Table E1). LPS-stimulated MDCCs conditioned
with cis-UCA, but not trans-UCA, had significantly reduced
expression of CD86 and PD-L1 compared with control values
on day 8 (CD86 MFI: 12,541 6 4,136 vs 15,490 6 5,150,
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P 5 .04; PD-L1 MFI: 256 6 118 vs 408 6 204, P 5 .02; Fig 5).
There were no significant changes in expression of HLA-DR,
CD40, CD1a, or CD11c (data not shown). MDCCs stimulated
with LTA showed a similar pattern of responses as LPS-
stimulated cells (data not shown). Cells harvested at day 9 showed
similar results to those harvested on day 7 or 8, indicating that
cis-UCA did not simply delay maturation (data not shown).
Cis-UCA–conditioned MDDCs induce regulatory
T cells in coculture
Cis-UCA–conditioned immature MDCCs did not affect
proliferation of CD4T cells at day 5 compared with control values
(Fig 6, A). However, CD4 T cells cocultured with cis-UCA–
conditioned MDCCs showed a higher proportion of
CD251FoxP31CD1272 cells at day 5 than those cultured with
trans-UCA–conditioned MDCCs (Fig 6, B-D). This effect was
not observed in CD4 T cells cocultured with cis-UCA–
conditioned LPS-stimulated MDCCs (data not shown).
DISCUSSION
Although phenotypically different subsets of APCs have been
identified in lesional AD skin, LCs are thought to be the only
APCs found in nonlesional epidermis.20,21 For many years, the
classic paradigm of LC function was of antigen uptake and
processing in the epidermis, followed by maturation and
migration to skin draining lymph nodes for antigen presentation
to T cells.22 This concept has recently been challenged by
observations that the majority of cutaneous lymphocyte anti-
gen–positive T cells are present in skin and that LCs can evoke
both tolerogenic and immunogenic T-cell responses.23
The ‘‘outside-inside’’ theory of AD pathogenesis proposes that
epidermal APCs in patients with AD will be exposed to more
danger signals through a deficient skin barrier, leading to APC
maturation and T cell–driven inflammatory skin disease. Using
confocal microscopy, we confirmed that all CD1a1HLA-DR1
epidermal cells from suction blister roof samples express
langerin, verifying that they are LCs. Although they are present
in similar numbers, are of similar size, and have a similar number
of dendrites per cell in each subject group, we demonstrate that
LCs from FLG-null subjects both with and without AD have
higher CD11c and CD83 expression than those of control
subjects.
CD11c is a member of the CD18 integrin family and is
expressed at a high level onmost dendritic cells24 but only at a low
level by LCs.25 It has previously been noted that some subjects
have LCs expressing higher levels of CD11c in combination
with increased HLA-DR expression.26 CD11c expression has
been shown to be upregulated in human LCs treated with retinoic
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FIG 3. Skin barrier function is reduced in FLG-null subjects with but not without AD. A, Comparison of mean
resting TEWL in all subject groups. P 5 .02, FLG-null subjects with AD versus WT subjects with AD,
Mann-Whitney test. Lines show minimum to maximum values. B, Plot showing the number of tape strips
required to reach a TEWL of greater than 20 g/h/m2 in all subject groups. P <_ .0001, Dunn multiple
comparison posttest values shown on graph. *P < .05 and ****P < .0001. Lines showminimum tomaximum
values.
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FIG 4. Cis-UCA reduces costimulatory molecule expression in unstimulated MDCCs. MDCCs were cultured
for 7 days in the presence of cis-UCA (c-UCA) or trans-UCA (t-UCA). Culture with 100 mg/mL cis-UCA caused
a significant reduction in CD86 (A), PD-L1 (B), HLA-DR (C), and CD40 (D) MFI. Statistical analysis was done
with repeated-measures ANOVA (Friedman test with Dunn multiple comparison posttest). **P < .01,
***P < .001, and ****P < .0001. Lines show medians and interquartile ranges.
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acid, and in the same experiment it was shown that a blocking
antibody to CD11c was able to completely abrogate the ability
of the LCs to present alloantigen to T cells, suggesting a critical
role in antigen presentation.27 A recent study using confocal
microscopy to observe the interaction between LCs and tight
junctions in patients with AD also found occasional LCs with
higher expression of HLA-DR, which they considered to be
activated LCs.28 CD83 is a well-characterized marker of dendritic
cell activation, which is expressed on mature LCs and might be
involved in T-cell activation.29,30 The upregulation of these
molecules suggests that in nonlesional skin FLG-null subjects
have more activated LCs compared with WT subjects.
In response to these findings, we investigated whether
FLG-null subjects had a measurably deficient skin barrier, which
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FIG 5. Cis-UCA reduces costimulatory molecule expression in LPS-stimulated MDCCs. MDCCs cultured for
7 days in the presence of cis-UCA (c-UCA) or trans-UCA (t-UCA) were stimulated with 1 ng/mL LPS
for 24 hours. Conditioning with 100 mg/mL cis-UCA caused a significant reduction in CD86 (A) and PD-L1
(B) MFI. Statistical analysis was done with repeated-measures ANOVA (Friedman test with Dunn multiple
comparison posttest). *P < .05 and **P < .01. Lines show medians and interquartile ranges.
FIG 6. Cis-UCA–conditioned MDCCs induce more cells with a regulatory T-cell phenotype. A, Proliferation
of CD4 T cells in coculture. B, Induction of cells with a regulatory T-cell phenotype after coculture. ns, Not
significant. *P < .05, Kruskal-Wallis test with the Dunn multiple comparison posttest. C, Similar proportion
of CD251 cells after coculture with trans-UCA– and cis-UCA–conditioned MDCCs. D, More
CD251FoxP31CD1272 cells after coculture with cis-UCA–conditioned MDCCs. In Fig 6, A, C, and D, Repre-
sentative plots from 1 donor are shown.
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could explain LC activation by increased exposure to danger
signals. We found that FLG-null subjects with AD had a
higher resting TEWL at baseline and required significantly
fewer tape strips to increase TEWL to greater than 20 g/m2/h
compared with WT subjects with AD (and control subjects),
indicating an intrinsic upper epidermal fragility. These findings
are in agreement with a recent study that used a similar
tape-stripping method.31 Interestingly, however, not only did
FLG-null subjects with normal skin show no difference in
resting TEWL at baseline compared with control subjects,
but also on physically challenging the epidermal barrier by
means of tape stripping, they were again no different to control
subjects. This implies that more than a genetic deficiency in
filaggrin is required to produce a functionally deficient skin
barrier.
To investigate why FLG-null subjects with physically
normal-appearing skin could have more mature epidermal LCs,
we studied the effects of the filaggrin breakdown product
cis-UCA on MDCCs. Concentrations of UCA in human skin, as
measured based on epidermal tape stripping, are known to vary
widely between subjects, ranging from 2 to 62 nmol/cm22
(equivalent to 40-1230 mg mL21).19 A maximum of 60% to
70% of the total UCA concentration can be in the cis isomer at
any time depending on recent UVR exposure,32 and both cis-
and trans-UCA are able to diffuse into the subepidermal
compartment (for more details, see the Methods section in this
article’s Online Repository).32-35
We demonstrate that cis-UCA, but not trans-UCA, is able to
downregulate the expression of CD86, HLA-DR, CD40, and
PD-L1 on immature MDCCs and the expression of CD86 and
PD-L1 on LPS-matured MDCCs. Our finding that immature
MDCCs conditioned with cis-UCA induce a higher proportion
of CD4 T cells with a regulatory T-cell phenotype in coculture
is in agreement with the results of a previously published study.36
If cis-UCA is able to exert a similar effect on LCs, which are
regarded as immature dendritic cells, in vivo this suggests a
potential role in maintaining tolerance in the epidermis by
preventing LCs from providing immunogenic signals to skin-
resident T cells and by increasing their ability to induce a local
regulatory T-cell phenotype. Additionally, because cis-UCA
levels are increased by UVR, this is also potentially a mechanism
for UVR-induced immunosuppression. Therefore a reduced level
of cis-UCA, as would be expected in subjects with FLG-null
mutations, could result in the LC maturation we observed in the
epidermal suction blister samples.
Although we did not identify significant differences in levels of
cis-UCA in suction blister fluid between the groups (see Fig E5 in
this article’s Online Repository at www.jacionline.org), a statisti-
cally significant stepwise decrease in total epidermal UCA levels
from healthy control subjects to WT subjects with AD, FLG-null
heterozygotes with AD, and FLG-null homozygotes with AD has
been reported based on a tape-stripping method to determine
UCA levels in the epidermis.37 Among patients with AD, FLG
genotype was the major determinant of UCA levels, with disease
severity as a secondary modifier.37
Our data do not address why some subjects with FLG-null
mutations have AD and others maintain a normal clinical
phenotype. If both groups of subjects have activated LCs in
their epidermis, potentially providing activating signals to
skin-resident T cells, it would suggest that there are overriding
tolerogenic mechanisms in those without skin inflammation.
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Key messages
d FLG-null subjects both with and without AD have more
mature LCs in their epidermis than control subjects.
d The cis-isomer of UCA, a filaggrin breakdown product, is
able to downregulate costimulatory molecule expression
of dendritic cells and increase their induction of a regula-
tory T-cell phenotype in cocultures in vitro.
d Relative UCA deficiency in FLG-null subjects might be a
mechanism for increased LC maturation and reduced
epidermal regulatory T-cell populations, resulting in in-
flammatory skin disease.
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METHODS
Antibody staining of epidermal APCs
Samples were stained with antibodies to CD1a (clone HI149–Alexa
Fluor 700), CD11c (clone 3.9–Alexa Fluor 488), and HLA-DR (clone
L243–phycoerythrin [PE]/Cy5) or isotype controls at 48C for 30 minutes.
Samples were then incubated with 1% SYTOX Blue Dead Cell Stain
(Invitrogen). All antibodies were purchased fromBioLegend (London, United
Kingdom).
Antibody staining panels for confocal microscopy
of suction blister roofs
Antibody panel 1 was as follows: antibodies to CD1a (clone HI149–Alexa
Fluor 647), CD1c (clone L161–Alexa Fluor 488), and CD207/langerin (clone
10E2) labeled with the Alexa Fluor 555 Monoclonal Antibody Labelling kit
(InvitrogenA-20187) and CD11c (Clone 3.9) labeledwith theAlexa Fluor 594
Monoclonal Antibody Labelling kit (Invitrogen A-20185). Antibody panel 2
was as follows: antibodies to HLA-DR (Clone L243–Alexa Fluor 647), CD83
(Clone HB15E–Alexa Fluor 488), and CD207/langerin (Clone 10E2) labeled
with the Alexa Fluor 555 Monoclonal Antibody Labelling kit (Invitrogen
A-20187), as before. Isotype control antibodies were used at identical
concentrations. All samples were stained with 49-6-diamidino-2-
phenylindole dihydrochloride (DAPI; Invitrogen) 1:1000 for 3 minutes and
then washed 3 times in PBS. All antibodies were purchased from BioLegend,
unless otherwise stated.
Antibody staining panels for flow cytometric
analysis of MDDCs
Antibody panel 1 was as follows: lineage cocktail-1 (antibodies to CD3,
CD14, CD16, CD19, CD20, and CD56–fluorescein isothiocyanate [FITC])
and antibodies to CD1a (clone HI149–Alexa Fluor 700, BioLegend), CD14
(clone MVP9–peridinin-chlorophyll-protein complex [PerCP]), CD40 (clone
5C3–APC, eBioscience), and CD86 (clone 2331-PE). Antibody panel 2 was as
follows: antibodies to CD80 (clone L307.4–Alexa Fluor 700), CD11c (clone
S-HCL-3–allophycocyanin), CD274/PDL (cloneM1H1-1–PE), and HLA-DR
(clone L243-ef450, eBioscience). The isotype antibodies IgG1 FITC (clone
MOPC-21), IgG2b FITC (clone MPC-11, BioLegend), IgG1 Alexa Fluor
700 (clone MOPC-21), IgG2b PerCP (clone MPC-11, BioLegend), IgG1
APC (clone MOPC-21), IgG1 PE (clone MOPC-21), IgG1 ef450 (clone
P3.6.2.8.1, eBioscience), and IgG2a ef450 (clone eBM2a, eBioscience) were
used at appropriate concentrations. EF780 viability dye (eBioscience) was
used to exclude dead cells. All antibodies were purchased from BD
Biosciences, unless otherwise stated.
Isolation of CD41 T cells from healthy volunteers
CD41 T cells were isolated by means of negative selection with the human
CD41 T cell enrichment kit from STEMCELL (Manchester, United
Kingdom), according to the manufacturer’s instructions. CD142 cells were
resuspended at 5 3 107 cells/mL in MACS buffer and incubated
with 50 mL/mL EasySep Human CD41 T Cell Enrichment Cocktail
for 10 minutes at room temperature. Cells were then incubated with
100 mL/mL EasySep D Magnetic Particles for 5 minutes before being diluted
with MACS buffer and incubated in Purple EasySep Magnet for 5 minutes.
The untouched CD41 T cells were poured off by inverting the magnet.
A sample of cells was stained with an FITC-conjugated CD4 antibody to
assess cell purity by using FACS analysis. Purity of the CD41 T cells was
consistently greater than 95%.
Antibody staining of CD41 T cells from mixed
leukocyte reactions
Cells were stained with CD4 (clone RPA-T4–PerCP), CD25 (clone
BC96–Alexa Fluor 488), CD127 (clone eBioRDR5–PE, eBioscience), and
FoxP3 (clone 206D–Alexa Fluor 647). All antibodies were purchased from
BioLegend, unless otherwise stated.
Supplemental material: Concentration of UCA
isomers in suction blister fluid
Both cis- and trans-UCA are able to diffuse into the subepidermal
compartment. After UV exposure, cis-UCA is measurable in suction blister
fluid for several weeks.E1,E2 It is also measurable in serum for 1 to 2 daysE3
and urine for 2 weeks.E4 One study compared levels of epidermal UCA
measured in blister roofs with levels of UCA in suction blister fluid in
nonirradiated and irradiated human skin. In nonirradiated skin cis-UCA
comprised 5% to 7% of epidermal UCA but was undetectable in blister fluid.
In irradiated skin, however, it comprised 55% of epidermal UCA and 53% to
59% of blister fluid UCA.E2
Suction blister fluid sampleswere collected from the cohort of subjects who
had suction blister roofs analyzed by using confocal microscopy (n 5 16).
Blister fluid was aspirated with a sterile needle attached to a 1-mL syringe,
transferred to an Eppendorf tube, and stored at 2808C until samples were
processed as a batch. Samples were analyzed by using high-performance
liquid chromatography–mass spectrometry.
Therewas no significant difference inmean levels of UCA in suction blister
fluid between groups, with mean concentrations ranging from 366 to
424 mmol/L (cis-UCA and trans-UCA isomers combined). The concentration
of cis-UCA was approximately 200-fold less than the concentration of
trans-UCA in all samples, making up only about 0.5% of the overall
concentration of UCA in the suction blister fluid (Fig E5).
We hoped to demonstrate a correlation between FLG genotype and UCA
levels in suction blister fluid from our subjects. Reported levels of UCA
present in suction blister fluid from nonirradiated human skin range from 35
to 100 mmol/L, with corresponding levels of the cis isomer comprising 0%
to 4% of the total UCA concentration.E1,E5 Levels of UCA in our suction
blister fluid samples were around 400 mmol/L, which was 4 times higher
than previously reported, whereas levels of cis-UCA comprised only about
0.5%of the total UCA present. Our sampleswere analyzed by using a different
method (high-performance liquid chromatography–mass spectrometry
compared with high-performance liquid chromatography alone), which might
account for the difference in our results, and were also collected over
the winter months in Scotland, which could result in a lower proportion of
cis-UCA compared with trans-UCA. Because the concentration of UCA in
our suction blister fluid samples was 10-fold less than that reported in
epidermal tape-stripping samples, it might be that in nonirradiated skin any
quantitative difference caused by a genetic mutation or inflammatory skin
disease detectable at the skin surface is imperceptible by the time the small
proportion diffuses into the dermal extracellular fluid sampled with the
suction blister technique. Epidermal tape stripping would have been a better
way to try and quantify differences in cis-UCA levels between our subject
groups.
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FIG E1. Gating strategy for single-cell suspensions created from epidermal suction blister roofs.
Representative FlowJo cytometry plots are shown. A, Forward scatter (FSC)–A, side scatter (SSC)–A plot
gated to exclude subcellular debris. B, SYTOX Blue SSC-A plot gated on live cells. C, HLA-DR: percentage
of the maximum histogram showing all epidermal cells gated on HLA-DR positivity. D, CD1a: percentage
of the maximum histogram showing HLA-DR1 cells gated on CD1a positivity. E, CD11c: percentage of the
maximum histogram showing HLA-DR1 and CD1a1 cells gated on CD11c positivity. F, CD11c expression
was divided into low and high groups to reflect the normal low expression of CD11c by LCs.
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FIG E2. Epidermal thickness of suction blister roof samples. The number of
1.01-mm z-stack slices needed to visualize each blister roof specimen was
calculated as a proxy measure of epidermal thickness. This scatter dot plot
shows mean values for each volunteer averaged from counts from 3
different stacks. Lines show means and SDs. P 5 .34, Kruskal-Wallis test.
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FIG E3. CD83 and HLA-DR staining of epidermal suction blister roofs. Intact suction blister roofs from
nonlesional skin were incubated with antibodies to CD1a, CD11c, CD83, HLA-DR, and langerin/CD207.
A, HLA-DR staining of epidermal dendritic cells (red) in a representative sample. Note that occasional cells
express more HLA-DR (arrows). B, CD83 staining showing occasional CD831 cells in the same sample
(green, arrows). C, Merged image showing that cells expressing more HLA-DR are also CD831 (arrows).
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FIG E4. Gating strategy for cultured cells. A, Representative FlowJo cytometry plots show that forward
scatter (FSC) versus side scatter (SSC) was used to draw a gate around the cells. B, Single cells were gated
by plotting FSC height against FSC area to exclude doublets. C, Viable cells were gated by excluding dead
cells stained with Ef780 dye. D, Single viable cells were then analyzed for individual markers, including
HLA-DR (lighter line), overlaid with their isotype controls. See Table E1 for full phenotypic details.
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FIG E5. Concentration of UCA isomers in suction blister fluid. A, Bar chart comparing mean levels of UCA
(cis-UCA and trans-UCA isomers combined) in suction blister fluid between different subject groups. The
narrow bar shows SEMs. P5 .66, Kruskal-Wallis test. B,Dot plot comparingmean levels of cis-UCA between
different subject groups. Bars show means 6 SEMs. P 5 .65, Kruskal-Wallis test. C, Dot plot comparing
mean levels of trans-UCA between different subject groups. Bars show means 6 SEMs. P 5 .66,
Kruskal-Wallis test. Note the approximately 200-fold difference between cis- and trans-UCA concentrations.
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TABLE E1. Flow cytometric measurement of dendritic cell markers after 7 days of culture and after a further 24 hours of incubation
in LPS
Marker Day 7 (%) Day 8, LPS 0.1 (%) Day 8, LPS 1.0 (%) MFI day 7 MFI day 8, LPS 0.1 MFI day 8, LPS 1.0
CD86 96 6 4 99 6 2 98 6 2 6,275 6 2,086 15,714 6 4,383 15,728 6 4,637
CD40 91 6 8 92 6 1 96 6 3 708 6 477 564 6 141 1,289 6 6,964*
HLA-DR 96 6 6 99 6 1 98 6 3 1,198 6 661 1,289 6 690 1,754 6 877
PD-L1 34 6 18 69 6 26* 77 6 28 153 6 85 401 6 328 549 6 377
CD80 61 6 32 83 6 14 83 6 12 412 6 206 617 6 199 745 6 231
CD1a 62 6 14 37 6 20* 34 6 22 742 6 363 273 6 109 409 6 378*
CD14 2 6 3 2 6 2 2 6 2 16 6 22 9 6 36 3 6 43
CD11c 96 6 4 99 6 1 97 6 4 5,517 6 1,280 6,530 6 1,890 7,384 6 2,987
Data are presented as means 6 SDs. CD86, CD40, HLA-DR, and CD11c were expressed by greater than 90% of cells at day 7. CD86 and CD40 increased in MFI after 24 hours of
LPS stimulation. CD80 percentage showed a nonsignificant increase after LPS and a significant change in MFI after incubation in the higher LPS concentration. The immature
dendritic cell marker CD1a was expressed by 61% of cells at day 7, but both percentage of positive cells and MFI decreased after incubation in LPS. The monocyte marker CD14
(expressed by all cells at the start of the culture period) was expressed at background levels at day 7 and was not altered by LPS stimulation. See the Methods section for culture
details.
One-way ANOVA (Kruskal-Wallis test with the Dunn posttest) showed significant P values, as indicated: *P < .05, P < .01, and P < .001 compared with the value on day 7.
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